Fluvastatin inhibits activation of JAK and STAT proteins in diabetic rat glomeruli and mesangial cells under high glucose conditions

Acta Pharmacologica Sinica

Volumn 28, Issue 12, 2007, Pages 1938-1946

  Shi, Yong Hong ^a   Zhao, Song ^a   Wang, Chen ^a   Li, Ying ^a   Duan, Hui Jun ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Fluvastatin; Janus kinase; Signal transducer and activators of transcription

Indexed keywords

ENZYME ANTIBODY; FIBRONECTIN; FLUINDOSTATIN; GLUCOSE; JANUS KINASE; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL LYSATE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GLOMERULUS; HYPERGLYCEMIA; IMMUNOBLOTTING; IMMUNOPRECIPITATION; KIDNEY PARENCHYMA; MALE; MESANGIUM; MESANGIUM CELL; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; UPREGULATION; URINALYSIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BASE SEQUENCE; DIABETIC RETINOPATHY; DNA PRIMERS; ENZYME ACTIVATION; FATTY ACIDS, MONOUNSATURATED; GLOMERULAR MESANGIUM; INDOLES; JANUS KINASES; MALE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT TRANSCRIPTION FACTORS;

EID: 36649027456     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00653.x     Document Type: Article

References (32)

1. Kim SI, Han DC, Lee HB. Lovastatin inhibits transforming growth factor-β1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000 11:80 7.
2. Oh JH, Ha H, Yu MR, Lee HB. Sequential effects of high glucose on mesangial cell transforming growth factor-β1 and fibronectin synthesis. Kidney Int 1998 54:1872 8.
3. Marrero MB, Banes AK, Stern DM, Eaton DC. Role of the JAK/ STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 2006 290:F762 8.
4. Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronection synthesis in mesangial cells. Diabetes 2002 51:3505 9.
5. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002 296:1653 5.
6. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to INFs and other extracellular signaling proteins. Science 1994 264:1415 21.
7. Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 2002 61:1605 16.
8. Amiri F, Venema VJ, Wang X, Ju H, Venema RC, Marrero MB. Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells. J Biol Chem 1999 274:32382 6.
9. Banes AK, Shaw S, Jenkins J, Redd H, Amiri F, Pollock DM, et al. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 2004 286:F653 9.
10. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl 1999 71:2 5.
11. Kurusu A, Shou I, Nakamura S, Fukui M, Shirato I, Tomino Y. Effects of the new hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin on anti-oxidant enzyme activities and renal function in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol 2000 27:767 70.
12. Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006 17:754 64.
13. Horiuchi M, Cui T, Li Z, Li J, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, vasartan, on vascular neointimal formation. Circulation 2003 107:106 12.
14. Banes AK, Shaw S, Ma G, Brands M, Eaton DC, Stern DM, et al. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol 2006 291:F116 21.
15. Amiri F, Garcia R. Renal angiotensin II receptors and protein kinase C in diabetic rats: effects of insulin and ACE inhibition. Am J Physiol Renal Physiol 2000 278:F603 12.
16. Amiri F, Garcia R. Regulation of angiotensin II receptors and PKC isoforms by glucose in rat mesangial cells. Am J Physiol 1999 276:F691 9.
17. Shah S, Paparello J, Danesh FR. Effects of statin therapy on the progression of chronic kidney disease. Adv Chronic Kidney Dis 2005 12:187 95.
18. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003 46:843 51.
19. Wolf G. Vasoactive factors and tubulointerstitial injury. Kidney Blood Press Res 1999 22:62 70.
20. Hannken T, Schroeder R, Stahl RAK, Wolf G. Atrial natriuretic peptide attenuates Ang II induced hypertrophy of renal tubular cells. Am J Physiol 2001 281:F81 90.
21. Ling H, Vamvakas S, Schaefer L, Schnittler HJ, Schaefer RM, Heidland A. Angiotensin II induced cell hypertrophy: potential role of impaired proteolytic activity in cultured LLcpk1 cells. Nephrol Dialysis Transplant 1995 10:1305 12.
22. Guo XH, Liu ZH, Dai CS, Li H, Liu D, Li LS. Rhein inhibits renal tubular epithelial cell hypertrophy and extracellular matrix accumulation induced by transforming growth factor β. Acta Pharmacol Sin 2001 22:934 8.
23. Park IS, Kiyomoto H, Abboud SL, Abboud HE. Expression of transforming growth factor β and type IV collagen in early streptozotocin-induced diabetes. Diabetes 1997 46:473 80.
24. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 2004 15:S55 7.
25. Marrero MB, Venema VJ, Ju H, Eaton DC, Venema RC. Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am J Physiol Cell Physiol 1998 275:C1216 23.
26. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002 9:387 99.
27. Denu JM, Tanner KG. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 1998 37:5633 42.
28. Ha H, Lee HB. Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 2003 14:S246 S249.
29. Schaefer CA, Kuhlmann CR, Weiterer S, Fehsecke A, Abdallah Y, Schaefer C, et al. Statins inhibit hypoxia-induced endothelial proliferation by preventing calcium-induced ROS formation. Atherosclerosis 2006 185:290 6.
30. 1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001 59:646 54.
31. Ali MS, Schieffer B, Delafontaine P, Bernstein KE, Ling BN, Marrero MB. Angiotensin II stimulates tyrosine phosphorylation and activation of insulin receptor substrate 1 and protein-tyrosine phosphatase 1D in vascular smooth muscle cells. J Biol Chem 1997 272:12373 9.
32. Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001 21:1896 901.